DWRX5004

DWRX5004 is a liquid formulation of botulinum toxin type A being developed by Daewoong Pharmaceutical in collaboration with Great Bear Pharmaceutical. Unlike conventional botulinum toxin products that are supplied as a lyophilized powder requiring reconstitution, DWRX5004 is a ready-to-use liquid, which aims to enhance clinical convenience and minimize the risk of dosing errors or contamination. The drug functions as a neurotoxin that enters peripheral cholinergic nerve terminals and cleaves the synaptosomal-associated protein 25 (SNAP-25). This cleavage disrupts the SNARE protein complex, preventing the fusion of synaptic vesicles with the cell membrane and thereby blocking the release of the neurotransmitter acetylcholine. This results in temporary chemo-denervation and muscle relaxation or reduced glandular secretion. DWRX5004 is currently in clinical development for aesthetic indications, such as the treatment of moderate to severe glabellar lines (facial wrinkles), and therapeutic indications, including primary axillary hyperhidrosis.

Other names

liquid botulinum toxin type A